Monitor for Form 4 filings to confirm whether the proposed sale is executed. The sustained selling by an officer over several weeks may signal a lack of confidence ahead of upcoming catalysts or earnings. Compare to any upcoming news or data readouts.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 5 $50.37entry
- T+1 · 5mo ago +1.97%α +1.74% · $51.36
- T+5 · 5mo ago +11.32%α +10.75% · $56.07
- T+20 · 4mo ago +23.70%α +21.84% · $62.31
- T+60 · 3mo ago +13.22%α +9.22% · $57.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 5, 2026, indicating intent to sell 20,000 common shares valued at approximately $1.04 million. The proposed sale follows a stock option exercise and is part of a broader pattern of insider selling, with Mulroy having sold over 126,000 shares in the prior three weeks across multiple transactions. While the filing itself is an advance notice of intent, the sustained selling by an officer warrants attention.
Key Facts
- Officer Dennis Mulroy filed Form 144 on June 5, 2026, to sell 20,000 shares valued at ~$1.04 million.
- The proposed sale follows a stock option exercise of 20,000 shares on June 4, 2026.
- Mulroy has sold a total of 126,422 shares between May 15 and June 3, 2026, with proceeds exceeding $7.2 million.
- The filing is an advance notice of intent; the sale may or may not be executed.
- No other insider activity or cross-filings are present in the provided context.
Financial Impact
Proposed sale of 20,000 shares at ~$1.04M; cumulative insider selling by this officer over past three weeks exceeds $7.2M.
Risk Factors
- Insider selling may indicate bearish sentiment or personal liquidity needs; sustained selling by an officer is a negative signal.
- The stock may face selling pressure if the proposed sale is executed and additional insider sales continue.
- No positive catalysts or cross-filings are present to offset the insider selling pattern.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-005679 |
| Document: 0001950047-26-005679-index.html | 0001950047-26-005679 |
| Document: 0001950047-26-005679.txt | 0001950047-26-005679 |
Track record
28 reports on ANAB
10 of 18 bullish or bearish reports moved the stock their way by T+1. Best: +41.26% at T+60 after the Mar 3, 2026 report. 13 of 18 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $46.25 Now $45.73 −1.12% settles Nov 17
- Nov 12, 20264d ago Press Release Bearish 4/10 Entry $46.25 to $45.73 Now $45.73 +1.12% ▲ +1.12% −0.79% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $46.45 to $47.97 Now $45.73 −1.55% ▲ +3.27% +0.91% vs SPY
- Sep 21, 20268w ago Press Release Neutral 5/10 Entry $53.92 to $50.77 Now $45.73 −15.19% ▼ −5.84% −5.12% vs SPY
- Aug 12, 202613w ago Institutional Cluster Bullish 5/10 Entry $56.02 to $58.47 Now $45.73 −18.37% ▲ +4.37% +4.57% vs SPY
- Jun 29, 202620w ago 144 Bearish 6/10 Entry $67.50 to $65.43 Now $45.73 +32.25% ▲ +3.07% +2.93% vs SPY
- Jun 29, 202620w ago DEFA14A Neutral 2/10 Entry $67.50 to $65.43 Now $45.73 −32.25% ▼ −3.07% −2.93% vs SPY
- Jun 26, 202620w ago 144 Bearish 6/10 Entry $65.97 to $67.50 Now $45.73 +30.68% ▼ −2.32% −1.54% vs SPY
- Jun 22, 202621w ago 8-K Neutral 2/10 Entry $59.43 to $58.48 Now $45.73 −23.05% ▼ −1.60% −1.55% vs SPY
- Jun 17, 202621w ago 144 Bearish 5/10 Entry $57.51 to $59.99 Now $45.73 +20.48% ▼ −4.31% −4.63% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers